Salute e Benessere

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2022 as well as the balance sheet and consolidated balance sheet as of 31 December 2022. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2022. The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2022 as well as the balance sheet and...
PR Newswire
30/05/2023

Magnetic Resonance Imaging System Market to Grow Exponentially by 2029-…

Key Takeaways Key Takeaways The Magnetic Resonance Imaging System Market is anticipated to garner significant returns over 2022-2029. Get Sample of Report@https://brandessenceresearch.com/downloadSample/PostId/286 Elaborating the Key Trends and Dynamics of Magnetic Resonance Imaging System Market The growing occurrence of chronic ailments, increased need for early disease diagnosis, and influx of advanced technologies in the disease diagnosis sector are primarily...
PR Newswire
30/05/2023

Medical Foods Market Size to Grow USD 27900 Million by 2029 at a CAGR of 5.4% |…

Major factors driving the growth of the Medical Foods Market: Major factors driving the growth of the Medical Foods Market : Over the next few years, the market expansion is predicted to be driven by the rising incidence of both communicable and non-communicable illnesses and the increased focus on the dietary control of such diseases. Over the next few years, the market is anticipated to be driven by the growing senior population, which is suffering from a variety of chronic and...
PR Newswire
30/05/2023

Medical Robotics Market to Grow Significantly by 2029- Brandessence Market…

Key Takeaways Key Takeaways The Medical Robotics Market is anticipated to grow substantially over the forecast duration of 2022-2029. Get Sample of Report@https://brandessenceresearch.com/downloadSample/PostId/283 Elaborating the Key Trends and Dynamics of Medical Robotics Market Growing prevalence of chronic and lifestyle-based disorders, increase in the number of surgeries, and rapid rise in the healthcare expenditure of various nations are the primary growth drivers of...
PR Newswire
30/05/2023

Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on…

Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control Proposal to appoint Jonathan Milner Executive Chairman of the BoardProposal to remove Peter Allen, Michael Baldock , and Sally Crawford as Directors of the Company ExecutiveChairman Milner intends torestore Abcam to the valuation it deservesCAMBRIDGE, England, 30May 2023– Jonathan Milner, the founder and one of the largest...
Nasdaq GlobeNewswire
30/05/2023

Electrolux Group sets provision mainly relating to French antitrust case

The provision communicated today relates to the second investigation. In February 2023, the Competition Authority issued a Statement of Objections involving various parties within the home appliance sector and where Electrolux France was alleged to have acted in breach of antitrust rules in France between 2009 and 2014. The provision communicated today relates to the second investigation. InFebruary 2023, the Competition Authorityissued a Statement of Objectionsinvolving various parties...
PR Newswire
30/05/2023

OLON Enters in ADC Market

OLON Group, a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and general markets, announces the start of construction of a new facility at its Rodano site (Milan, Italy) which will be entirely dedicated to managing and producing Ultra-Potent compounds, used for example as payloads and payload-linkers for antibody-drug conjugates (ADCs), one of the most promising emerging cancer therapies, which combines the effective killing power of small...
Nasdaq GlobeNewswire
30/05/2023

Cepheid Receives CE Mark for Xpert® NPM1 Mutation

The European LeukemiaNet recommends quantitative molecular assessment of NPM1 by qPCR as part of minimal residual disease (MRD) monitoring of patients with NPM1-mutated AML1. The European LeukemiaNet recommends quantitative molecular assessment of NPM1 by qPCR as part of minimal residual disease (MRD) monitoring of patients with NPM1-mutated AML 1. Acute myeloid leukemia (AML) is a cancer of the myeloid blood hematopoietic stem cells in the bone marrow and is known to have various...
PR Newswire
30/05/2023

SK bioscience Receives Marketing Authorization of COVID-19 Vaccine from UK MHRA

Jaeyong Ahn, CEO of SK bioscience said, "We are delighted with the MHRA's authorization of Korea's first COVID-19 vaccine SKYCovion. This is the result of our commitment to protecting and promoting global public health. We are confident it will be the milestone to solidify our position in the global market amid the transition of the pandemic to the endemic phase." Jaeyong Ahn, CEO of SK bioscience said, "We are delighted with the MHRA's authorization of Korea's first COVID-19…
PR Newswire
30/05/2023

Aurora and Ethypharm Reaffirm their Commitment to Promote Access to Medical…

"We are delighted to have been selected once again to continue to supply high quality dried medical cannabis flower to the French pilot program. Driven by our purpose of opening the world to cannabis, Aurora continues to work hand-in-hand with government officials, physicians and pharmacists to reduce stigma and further develop medical markets throughout Europe," says Dr. Axel Gille, President of Aurora Europe. "We are delighted to have been selected once again to continue to…
PR Newswire
30/05/2023

Global Cytotoxic Drug Market Expected to Grow Substantially Owing to Rising…

As per the report published by Research Dive, the global cytotoxic drug market is expected to register a revenue of $21,644.10 million by 2031 at a CAGR of 5.7% during the forecast period 2022-2031. As per the report published by Research Dive, theglobal cytotoxic drug market is expected to register a revenue of$21,644.10 millionby 2031 at a CAGR of 5.7% during the forecast period 2022-2031. Segments of the Cytotoxic Drug Market The report has divided the cytotoxic drug market...
PR Newswire
30/05/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 30May 2023– On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the...
Nasdaq GlobeNewswire
30/05/2023

[Latest Report] Intraocular Lens Market is estimated to be US$ 7.9 billion by…

Intraocular Lenses (IOLs) are artificial, permanent lenses which can replace eye's natural lens for restoring near & distant vision. Firstly, lens is removed by process called as phacoemulsification. Small incision is made in edge of cornea, then lens is broken into small pieces & are rinsed from eye, then IOL is folded & inserted through small incision so that it can rest in same clear capsule where natural lens once did. Intraocular Lenses (IOLs) are artificial, permanent lenses…
PR Newswire
30/05/2023

Tessa Therapeutics' Autologous and Allogeneic Cell Therapy Data to be Featured…

New data from clinical trials of TT11 and TT11X to be featured in oral and poster presentations Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced two presentations featuring clinical data from the company's autologous CD30.CAR-T therapy TT11 and off-the-shelf CD30 CAR EBVST therapy (TT11X) will be featured at the 17th International Conference on Malignant...
Nasdaq GlobeNewswire
30/05/2023

Global Smart Scale Market to Surpass USD 5.54 Billion By 2031| Growth Market…

Download PDF Sample here: https://growthmarketreports.com/request-sample/4713 Download PDF Sample here: https://growthmarketreports.com/request-sample/4713 The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics. It provides an in-depth analysis of the market segments, which include type, application, distribution channel, and competitor analysis. This report also includes a complete analysis...
PR Newswire
30/05/2023

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and…

Hellen De Kloet, Business Head - Western Europe and ANZ, Sun Pharma, said, "We are delighted to partner with Philogen for Nidlegy™, a close to market, new immunotherapy treatment in skin cancers. This collaboration is in line with our goal to bring innovative products to patients. With the expected addition of Nidlegy™ to our existing Odomzo™ franchise, we will be well-positioned to provide patient solutions across a broad spectrum of skin cancers in various disease stages." Hellen De…
PR Newswire
30/05/2023

Metformin Hydrochloride Market to Surpass USD 602.81 Million By 2031| Growth…

Download PDF Sample here: https://growthmarketreports.com/request-sample/4782 Download PDF Sample here: https://growthmarketreports.com/request-sample/4782 The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics. It provides an in-depth analysis of the market segments, which include type, distribution channel, and competitor analysis. This report also includes a complete analysis of industry...
PR Newswire
30/05/2023

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance…

The new agreement further broadens and expands the existing collaboration between Adcendo and Duality. Based on the agreement, new targets will be evaluated under MTA with Duality's linker-payload platform, designed to generate ADCs with superior safety profiles, sustainable payload delivery and release in tumors, and efficient bystander killing of antigen low and negative cells. Following evaluation, Adcendo has the option to gain access to Duality's next generation ADC platform. The new...
PR Newswire
30/05/2023

Registration of share capital increase of 13,719,337 new shares completed

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURESTHIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFERING MEMORANDUM OR A PROSPECTUS AS DEFINED BY REGULATION (EU) NO. 2017/1129 OF 14 JUNE 2017. Registration of share capital increase of 13,719,337new shares...
Nasdaq GlobeNewswire
30/05/2023

Implantica's RefluxStop™ Wins Medtop Tech's Most Innovative Device Category…

The Medtop Tech Award is assigned to medical devices and equipment that distinguishes a certain product from its competitors. Dr. Peter Forsell accepted the award during a live broadcast event which included more than 300 online guests and attendees from 16 countries. The Medtop Tech Award is assigned to medical devices and equipment that distinguishes a certain product from its competitors. Dr.Peter Forsellaccepted the award during a live broadcast event which included more than 300 online...
PR Newswire
30/05/2023

Hansa announces first patient dosed with imlifidase in a global pivotal phase 3…

GOOD-IDES-02 is an open label, multi-center, phase 3 trial of 50 patients. A total of 30-40 centers are expected to be included in the study across the US, UK, and EU. The primary objective of the study is to assess the superior effect of imlifidase in combination with standard of care (SoC) versus SoC alone (consisting of a combination of immunosuppressives, glucocorticoids, and plasma exchange) in the treatment of patients affected by severe anti-GBM disease. The performance of the treatment…
PR Newswire
30/05/2023

Idorsia announces a change to commercial leadership

Ad hoc announcement pursuant to Art. 53 LR Simon Jose to step down from his position as Chief Commercial Officer and member of the Idorsia Executive Committee to pursue other opportunitiesOtto Schwarz will advise the management team on commercial operationsAllschwil, Switzerland – May30 , 2023Idorsia Ltd (SIX: IDIA) today announced that Simon Jose will leave his position as Chief Commercial Officer and member of the Idorsia Executive Committee to pursue other opportunities...
Nasdaq GlobeNewswire
30/05/2023

Valneva Files for Chikungunya Vaccine Authorization with Health Canada

Saint-Herblain (France) , May30 , 2023–ValnevaSE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company's single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above. If accepted, Health Canada will provide additional information on the potential approval timeline.This is the second regulatory application for VLA1553...
Nasdaq GlobeNewswire
30/05/2023

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and…

Mumbai, India and Siena, Italy, 30 thMay2023– Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen's specialty product, Nidlegy™ (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy™, currently in Phase...
Nasdaq GlobeNewswire
30/05/2023
Altri  Comunicati